MARKET

CAPR

CAPR

Capricor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.380
-0.180
-3.95%
After Hours: 4.420 +0.04 +0.91% 18:09 07/10 EDT
OPEN
4.540
PREV CLOSE
4.560
HIGH
4.555
LOW
4.320
VOLUME
480.14K
TURNOVER
--
52 WEEK HIGH
11.08
52 WEEK LOW
0.8800
MARKET CAP
62.48M
P/E (TTM)
-2.6355
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CAPR stock price target is 10.50 with a high estimate of 12.00 and a low estimate of 9.00.

EPS

CAPR News

More
CLDX, AMC among premarket gainers
Seeking Alpha - Article · 06/10 13:15
Capricor to Participate in BIO Digital International Convention
GlobeNewswire · 06/04 14:15
Here is What Hedge Funds Think About Capricor Therapeutics, Inc. (CAPR)
Insider Monkey · 05/29 18:08
70 Biggest Movers From Yesterday
Gainers Cheetah Mobile Inc. (NYSE: CMCM) shares surged 47.3% to close at $3.05 on Wednesday after the company reported a $1.44 per ADS special dividend and agreed to sell remaining equity ownership in Bytedance for $66 million.
Benzinga · 05/21 09:22
52 Stocks Moving In Wednesday's Mid-Day Session
Gainers AeroCentury Corp. (NYSE: ACY) shares jumped 80.3% to $3.9305.
Benzinga · 05/20 17:17
DS, RENN, ACB and PYX among midday movers
Seeking Alpha - Article · 05/20 16:42
Capricor Therapeutics Inc. (CAPR) CEO Linda Marban on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/18 15:34
Capricor Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation
Seeking Alpha - Article · 05/18 11:20

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
More

Webull offers kinds of Capricor Therapeutics Inc stock information, including NASDAQ:CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.